This partner is going to buy GenPrecis sight unseen.
I often forget that this is a stock message board and many who post here do not understand how a business operates. Many who post here believe that because they once (or often) owned stock in larger or well run companies, it means that they as posters understand how businesses operate. Not, not, not true! DECN is not going to sell the product GenPrecis to a partner, as in sale of technology. It means that the partner wants to be a partner based on the promise of GenPrecis. The partner wants to carry the product along with all of the other product they sell .... all of this sight unseen. By the way, the partner is also going to carry GenUltimate and GenChoice.
And, J&J is about to find out about another litigation front that will double Amazon sales thanks to a "friend" in Brooklyn, NY.
J&J currently allows importation, the actual term is "parallel importation," of its South American package. The industry calls this product the "three language" Onetouch Ultra. The importation of this package used to be very popular (2004-2014), because the cost of this South American package for importers was about $18 (Note: Medicare and all insurers do not reimburse for this product type because it does not have an NDC registration number). In late 2014 J&J put out a (legal) port of entry embargo on "3 language" Ultra, enforced by the FDA.
Then when sales of test strips exploded on Amazon and Walmart in 2015, 2016 and 2017, J&J eased parallel import again because this package competed directly with GenUltimate. Returning the embargo for this product, and to a lesser degree the English/French/Arabic package that is also parallel imported, will end sales of this product on Amazon, effectively doubling GenUltimate sales and adding a new group of distributors. A three front battle will shortly ensue against J&J, the FDA and Amazon. Amazon will, in my opinion, cave in first.
However, these will make it crystal clear that this company has significantly more to offer...
Not that I set out to bash DECN bashers (although it is sooooo easy), but most message board posters don't have a clue about how hard it is to be a small company and have a product that scares the big boys. My area of expertise in this industry is marketing. I certainly understand the concept of "barriers to market entry." The barriers to market entry are not free for DECN. Costs of entry are large and resources to overcome these barriers are required. DECN bashers, and non-industry, non-business experienced vocal doubters just don't understand (or care to) this. For them it is always about share price.
I often forget that this is a stock message board and many who post here do not understand how a business operates. Many who post here believe that because they once (or often) owned stock in larger or well run companies, it means that they as posters understand how businesses operate. Not, not, not true! DECN is not going to sell the product GenPrecis to a partner, as in sale of technology. It means that the partner wants to be a partner based on the promise of GenPrecis. The partner wants to carry the product along with all of the other product they sell .... all of this sight unseen. By the way, the partner is also going to carry GenUltimate and GenChoice.
And, J&J is about to find out about another litigation front that will double Amazon sales thanks to a "friend" in Brooklyn, NY.
J&J currently allows importation, the actual term is "parallel importation," of its South American package. The industry calls this product the "three language" Onetouch Ultra. The importation of this package used to be very popular (2004-2014), because the cost of this South American package for importers was about $18 (Note: Medicare and all insurers do not reimburse for this product type because it does not have an NDC registration number). In late 2014 J&J put out a (legal) port of entry embargo on "3 language" Ultra, enforced by the FDA.
Then when sales of test strips exploded on Amazon and Walmart in 2015, 2016 and 2017, J&J eased parallel import again because this package competed directly with GenUltimate. Returning the embargo for this product, and to a lesser degree the English/French/Arabic package that is also parallel imported, will end sales of this product on Amazon, effectively doubling GenUltimate sales and adding a new group of distributors. A three front battle will shortly ensue against J&J, the FDA and Amazon. Amazon will, in my opinion, cave in first.
However, these will make it crystal clear that this company has significantly more to offer...
Not that I set out to bash DECN bashers (although it is sooooo easy), but most message board posters don't have a clue about how hard it is to be a small company and have a product that scares the big boys. My area of expertise in this industry is marketing. I certainly understand the concept of "barriers to market entry." The barriers to market entry are not free for DECN. Costs of entry are large and resources to overcome these barriers are required. DECN bashers, and non-industry, non-business experienced vocal doubters just don't understand (or care to) this. For them it is always about share price.
7
